Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details Narrative)

Commitments and Contingencies (Details Narrative) - USD ($)								1 Months Ended	12 Months Ended
	Nov. 18, 2024	May 20, 2024	May 13, 2024	May 13, 2022	Jun. 16, 2021	Mar. 26, 2021	Jul. 18, 2016	May 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Nov. 21, 2024	Jun. 30, 2024	Apr. 25, 2024	Aug. 24, 2022
Loss Contingencies [Line Items]
Loss Contingency, Damages Sought, Value				$ 470,000
Treasury Stock, Common, Shares				13,902
Legal fee								$ 473,000	$ 473,000
Shares return, value								$ 19,000
Shares return								13,902
Common stock, shares issued									2,234,328	1,380,633
Stock issued during period, value, issued for services									$ 1,100,000	$ 430,000
Research and development expense									5,798,000	6,466,000
Contigency minimum required											$ 2,500,000
2021 Scientific Research Agreement [Member]
Loss Contingencies [Line Items]
Aggregate research and development expense					$ 2,100,000
Research and development expense									0	192,000
2023 Sponsored Research Agreement [Member]
Loss Contingencies [Line Items]
Aggregate research and development expense		$ 1,700,000
Research and development expense									1,078,000	0
Unbilled and unaccrued amounts									647,000
2016 Patent Exclusive License Agreement [Member]
Loss Contingencies [Line Items]
Research and development expense									145,000	0
Proceeds from upfront amount			$ 145,000				$ 200,000
Maintenance fee			$ 100,000				$ 100,000
Royalty fee percentage			6.00%				4.00%
Performance milestone payments			$ 3,100,000				$ 3,100,000
Sales milestone payments			1,000,000				1,000,000
Gross sales			250,000,000				250,000,000
Sales revenue			5,000,000				5,000,000
Cumulative gross sales			500,000,000				$ 500,000,000
Royalty expense year one			250,000
Royalty expense years two through five			2,000,000
Royalty expense year six and thereafter			$ 5,000,000
2016 Patent Exclusive License Agreement [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Royalty fee percentage			5.00%				6.00%
2016 Patent Exclusive License Agreement [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Royalty fee percentage			1.00%
2016 Patent Exclusive License Agreement [Member] \| 2017 through 2020 [Member]
Loss Contingencies [Line Items]
Maintenance fee							$ 200,000
2016 Patent Exclusive License Agreement [Member] \| 2022 [Member]
Loss Contingencies [Line Items]
Annual royalty payments							250,000
2016 Patent Exclusive License Agreement [Member] \| 2025 [Member]
Loss Contingencies [Line Items]
Maintenance fee			$ 50,000
Annual royalty payments							2,000,000
2016 Patent Exclusive License Agreement [Member] \| 2027 [Member]
Loss Contingencies [Line Items]
Annual royalty payments							$ 5,000,000
2021 Patent License Agreement [Member]
Loss Contingencies [Line Items]
Maintenance fee						$ 2,000,000
Annual royalty payments						250,000
Performance milestone payments						3,100,000
Sales milestone payments						1,000,000
Gross sales						250,000,000
Sales revenue						5,000,000
Cumulative gross sales						500,000,000
Upfront license fee						20,000
License maintenance fee, receivable						$ 5,000
2021 Patent License Agreement [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Royalty fee percentage						5.00%
2021 Patent License Agreement [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Royalty fee percentage						2.50%
2024 GTB-3650 Clinical Trial Agreement [Member]
Loss Contingencies [Line Items]
Research and development expense									190,000	0
Unbilled and unaccrued amounts									1,800,000
Annual royalty payments	$ 2,000,000
Cytovance Biologics Inc [Member]
Loss Contingencies [Line Items]
Research and development expenses									2,335,000	4,584,000
Cash payments									$ 3,857,000	$ 2,213,000
Common stock, shares issued									127,597	57,437
Accounts payable									$ 810,000	$ 1,120,000
Cytovance Biologics Inc [Member] \| Research and Development Expense [Member]
Loss Contingencies [Line Items]
Research and development expenses									$ 2,335,000	$ 4,584,000
Cytovance Biologics Inc [Member]
Loss Contingencies [Line Items]
Equity method investment, ownership percentage												5.00%	9.90%	4.90%